EGFR and non-small cell lung carcinoma: Recently, the IMpower150 treatment model (bevacizumab+ICIs+chemotherapy) was approved as the standard first‐line option for patients with NSCLC without oncogenic drivers or with sensitive EGFR mutations who are resistant to EGFR‐TKIs.21